Related Experiment Video
Updated: May 19, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Cytostatic in vitro effects of DTCM-glutarimide on bladder carcinoma cells
María S Brassesco1, Julia A Pezuk, Andressa G Morales
1Division of Pediatric Oncology, Department of Pediatrics, Faculty of Medicine of Ribeirao Preto, University of São Paulo-USP, Brazil. marsol@rge.fmrp.usp.br
Abstract:
Bladder cancer is a common malignancy worldwide. Despite the increased use of cisplatin-based combination therapy, the outcomes for patients with advanced disease remain poor. Recently, altered activation of the PI3K/ Akt/mTOR pathway has been associated with reduced patient survival and advanced stage of bladder cancer, making its upstream or downstream components attractive targets for therapeutic intervention. In the present study, we showed that treatment with DTCM-glutaramide, a piperidine that targets PDK1, results in reduced proliferation, diminished cell migration and G1 arrest in 5637 and T24 bladder carcinoma cells. Conversely, no apoptosis, necrosis or autophagy were detected after treatment, suggesting that reduced cell numbers in vitro are a result of diminished proliferation rather than cell death. Furthermore previous exposure to 10 μg/ml DTCM- glutarimide sensitized both cell lines to ionizing radiation. Although more studies are needed to corroborate our findings, our results indicate that PDK1 may be useful as a therapeutic target to prevent progression and abnormal tissue dissemination of urothelial carcinomas.
Insights
DTCM-glutaramide, targeting PDK1, reduces bladder cancer cell proliferation and migration. Pre-treatment with this compound also sensitizes cancer cells to ionizing radiation, suggesting PDK1 as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Bladder cancer is a prevalent malignancy with poor outcomes in advanced stages, even with cisplatin therapy.
- The PI3K/Akt/mTOR pathway is frequently altered in bladder cancer, correlating with poor survival and advanced disease.
- Targeting components of this pathway presents a promising therapeutic strategy for bladder cancer.
Purpose of the Study:
- To investigate the effects of DTCM-glutaramide, a PDK1 inhibitor, on bladder carcinoma cell lines.
- To evaluate the potential of DTCM-glutaramide as a therapeutic agent for bladder cancer.
- To assess the radiosensitizing properties of DTCM-glutaramide in bladder cancer cells.
Main Methods:
- Treatment of 5637 and T24 bladder carcinoma cells with DTCM-glutaramide.
- Assessment of cell proliferation, migration, cell cycle arrest, apoptosis, necrosis, and autophagy.
- Evaluation of the combined effect of DTCM-glutaramide and ionizing radiation on cancer cells.
Main Results:
- DTCM-glutaramide treatment led to reduced proliferation, diminished cell migration, and G1 arrest in bladder cancer cells.
- No significant apoptosis, necrosis, or autophagy was observed, indicating proliferation inhibition as the primary effect.
- Previous exposure to DTCM-glutaramide sensitized both cell lines to ionizing radiation.
Conclusions:
- PDK1 inhibition by DTCM-glutaramide effectively reduces bladder carcinoma cell proliferation and migration.
- DTCM-glutaramide exhibits radiosensitizing effects, suggesting a potential role in combination therapy for bladder cancer.
- PDK1 is a viable therapeutic target for preventing the progression and dissemination of urothelial carcinomas.
